Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2017 11:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi

GAITHERSBURG, Md., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Sanofi’s ACAM2000®, (Smallpox (Vaccinia) Vaccine,...
October 04, 2017 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector

GAITHERSBURG, Md., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S....
October 03, 2017 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK

Transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017 GAITHERSBURG, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Emergent...
October 02, 2017 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Announces Closing of New $200 Million Senior Secured Credit Facility

GAITHERSBURG, Md., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed a new five-year, $200 million syndicated senior secured credit...
September 25, 2017 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 Million

GAITHERSBURG, Md., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a five-year follow-on contract valued at up to approximately $171...
September 18, 2017 08:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure

GAITHERSBURG, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at approximately $63 million by the Biomedical...
August 03, 2017 16:15 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance

GAITHERSBURG, Md., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2017. FINANCIAL HIGHLIGHTS (in...
July 31, 2017 16:15 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense

GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $23 million to develop a novel multi-drug...
July 26, 2017 16:15 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology

Parties to collaborate through Phase 1 clinical development Phase 1 trial expected to commence in late 2017 or early 2018 GAITHERSBURG, Md., July 26, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions...
July 20, 2017 07:00 ET | Source: Emergent BioSolutions Inc.

Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017

GAITHERSBURG, Md., July 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will release its second quarter financial results immediately after market close on Thursday, August 3,...